Comparative study of gemcitabine and cisplatin versus navelbine and cisplatin in the treatment of advanced non-small-cell lung cancer
- VernacularTitle:GP方案与NP方案治疗非小细胞肺癌疗效及药物经济学评价
- Author:
Danmei PANG
;
Ping LUO
;
Yicong TANG
;
Jianmiao LIANG
- Publication Type:Journal Article
- Keywords:
Gemcitabine;
Cisplatin;
Navelbine;
Non-small-cell lung cancer
- From:
Cancer Research and Clinic
1999;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
0.05). The major toxic reactions in the two groups was tolerable myelo-suppression. The average cost of one patient for two therapeutic cycles was (23664?384.7) and (8519.94?369.1) respectively. Escalation of 1 % of response rate costed (485.02?34.65) and (185.62?23.77) respectively. Prolongation of 1 month of median survival duration costed (2211.59?59.1) and (946.66?43.3) respectively.TTP in group GP is longer than that in group NP(P
